These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 30796122)

  • 61. Phosphate Toxicity in CKD: The Killer among Us.
    Ritter CS; Slatopolsky E
    Clin J Am Soc Nephrol; 2016 Jun; 11(6):1088-1100. PubMed ID: 26912542
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Sevelamer Versus Calcium-Based Binders for Treatment of Hyperphosphatemia in CKD: A Meta-Analysis of Randomized Controlled Trials.
    Patel L; Bernard LM; Elder GJ
    Clin J Am Soc Nephrol; 2016 Feb; 11(2):232-44. PubMed ID: 26668024
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V; Torregrosa V
    Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Role of Chronic Kidney Disease (CKD)-Mineral and Bone Disorder (MBD) in the Pathogenesis of Cardiovascular Disease in CKD.
    Yamada S; Nakano T
    J Atheroscler Thromb; 2023 Aug; 30(8):835-850. PubMed ID: 37258233
    [TBL] [Abstract][Full Text] [Related]  

  • 65. FGF-23 and Phosphate in Children with Chronic Kidney Disease: A Cross-Sectional Study in Kazakhstan.
    Balmukhanova A; Kabulbayev K; Alpay H; Kanatbayeva A; Balmukhanova A
    Medicina (Kaunas); 2020 Dec; 57(1):. PubMed ID: 33379157
    [No Abstract]   [Full Text] [Related]  

  • 66. Hyperphosphatemia with elevated serum PTH and FGF23, reduced 1,25(OH)
    Kritmetapak K; Losbanos L; Berent TE; Ashrafzadeh-Kian SL; Algeciras-Schimnich A; Hines JM; Singh RJ; Kumar R
    BMC Nephrol; 2021 Mar; 22(1):114. PubMed ID: 33784965
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Examining the effects of uric acid-lowering on markers vascular of calcification and CKD-MBD; A post-hoc analysis of a randomized clinical trial.
    Andrews ES; Perrenoud L; Nowak KL; You Z; Pasch A; Chonchol M; Kendrick J; Jalal D
    PLoS One; 2018; 13(10):e0205831. PubMed ID: 30356327
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Restoration of parathyroid function after change of phosphate binder from calcium carbonate to lanthanum carbonate in hemodialysis patients with suppressed serum parathyroid hormone.
    Inaba M; Okuno S; Nagayama H; Yamada S; Ishimura E; Imanishi Y; Shoji S
    J Ren Nutr; 2015 Mar; 25(2):242-6. PubMed ID: 25556148
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Fibroblast growth factor 23 and parathyroid hormone after treatment with active vitamin D and sevelamer carbonate in patients with chronic kidney disease stage 3b, a randomized crossover trial.
    Bleskestad IH; Bergrem H; Hartmann A; Godang K; Gøransson LG
    BMC Nephrol; 2012 Jun; 13():49. PubMed ID: 22742720
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia.
    Joy MS; Finn WF;
    Am J Kidney Dis; 2003 Jul; 42(1):96-107. PubMed ID: 12830461
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Effects of oral activated charcoal on hyperphosphatemia and vascular calcification in Chinese patients with stage 3-4 chronic kidney disease.
    Gao Y; Wang G; Li Y; Lv C; Wang Z
    J Nephrol; 2019 Apr; 32(2):265-272. PubMed ID: 30588573
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Progression of arterial stiffness is associated with changes in bone mineral markers in advanced CKD.
    Krishnasamy R; Tan SJ; Hawley CM; Johnson DW; Stanton T; Lee K; Mudge DW; Campbell S; Elder GJ; Toussaint ND; Isbel NM
    BMC Nephrol; 2017 Sep; 18(1):281. PubMed ID: 28870151
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Effect of aluminum hydroxide on serum phosphate and fibroblast growth factor 23 concentrations in young adult cats with surgically induced chronic kidney disease.
    Beita KG; Lourenço BN; Rehagen M; Schmiedt CW
    Am J Vet Res; 2024 Oct; 85(10):. PubMed ID: 39137806
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease.
    Isakova T; Wahl P; Vargas GS; Gutiérrez OM; Scialla J; Xie H; Appleby D; Nessel L; Bellovich K; Chen J; Hamm L; Gadegbeku C; Horwitz E; Townsend RR; Anderson CA; Lash JP; Hsu CY; Leonard MB; Wolf M
    Kidney Int; 2011 Jun; 79(12):1370-8. PubMed ID: 21389978
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Hyperphosphatemia and phosphate binders: effectiveness and safety.
    Kalaitzidis RG; Elisaf MS
    Curr Med Res Opin; 2014 Jan; 30(1):109-12. PubMed ID: 24007207
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Design and baseline characteristics of the LANDMARK study.
    Ogata H; Fukagawa M; Hirakata H; Kaneda H; Kagimura T; Akizawa T;
    Clin Exp Nephrol; 2017 Jun; 21(3):531-537. PubMed ID: 27405619
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Vitamin K Supplementation to Improve Vascular Stiffness in CKD: The K4Kidneys Randomized Controlled Trial.
    Witham MD; Lees JS; White M; Band M; Bell S; Chantler DJ; Ford I; Fulton RL; Kennedy G; Littleford RC; McCrea IV; McGlynn D; Panarelli M; Ralston MR; Rutherford E; Severn A; Thomson N; Traynor JP; Struthers AD; Wetherall K; Mark PB
    J Am Soc Nephrol; 2020 Oct; 31(10):2434-2445. PubMed ID: 32817311
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). Lanthanum carbonate and new phosphate binders in patients with chronic kidney disease].
    Negi S; Shigematsu T
    Clin Calcium; 2010 Jul; 20(7):1096-102. PubMed ID: 20585189
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Control of phosphorus and treatment with vitamin D in chronic kidney disease prior to the start of dialysis].
    Sánchez González MC; Fernandez Giraldez E; Valdivielso Revilla JM
    Nefrologia; 2008; 28 Suppl 5():39-45. PubMed ID: 18847419
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Methodology and Baseline Data of a Comparative Exploratory Double-Blinded Randomized Study of Intravenous Iron on Fibroblast Growth Factor 23 and Phosphate in Chronic Kidney Disease.
    Kassianides X; Bhandari S
    Kidney Blood Press Res; 2023; 48(1):151-164. PubMed ID: 37015198
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.